Decreased Plasma MANF Levels Are Associated with Type 2 Diabetes.

Wang Cong,Jia,Miao He,Liu Dong Fang,Li

DOI: https://doi.org/10.3967/bes2021.030

IF: 2.831

2021-01-01

Biomedical and Environmental Sciences

Abstract:Type 2 diabetes mellitus (T2DM) is a multifactorial disease caused by both genetic and environmental factors. Although many genes have been reported to be involved in T2DM, much is still unknown about other genes that are involved in the disease and its progression. Therefore, the exploration of new factors plays a pivotal role in the development of new methods and strategies to prevent this chronic disease. Mesencephalic astrocyte-derived neurotrophic factor (MANF) is a soluble secretory protein located in the endoplasmic reticulum. MANF has primarily been shown to play neuroprotective and neurorestorative roles in the nervous system. Recent studies indicate that MANF plays a potential role in food intake and energy homeostasis and is involved in the regulation of metabolic diseases. Loss of MANF accelerated lipogenesis and aggravated HepG2 cell steatosis, while MANF overexpression inhibited lipogenesis and rescued HepG2 cell steatosis resulting from free fatty acid treatment. Most importantly, mice with systemic MANF deficiencies had severe diabetes, and MANF protected β cells against glucotoxicity and was indispensable for the proliferation and survival of pancreatic beta cells. Thus, it is reasonable to expect that circulating MANF levels may be significantly decreased during the diabetic state. However, there are contradictory results regarding the levels of circulating MANF in diabetic patients. Plasma MANF concentration was increased compared to controls, in newly diagnosed prediabetes and that T2DM and in children with T1DM. These results led us to investigate whether elevated circulating MANF levels are simply a compensatory response, especially in T2DM patients. Therefore, the aims of the present study were to investigate the relationship between the plasma MANF concentration and T2DM and to determine the clinical factors that are correlated with MANF levels in this population. One hundred seventy-four individuals were enrolled in this study from 12/2015 to 01/2018 during their admission to the Second Affiliated Hospital of Chongqing Medical University or during an outpatient health check-up. Subjects were divided into 3 groups: 1) healthy controls with normal body mass index (BMI < 25 kg/m) and normal fasting glucose, n = 40; 2) overweight and obese subjects with BMI > 25 kg/m, n = 78; and 3) T2DM patients with durations of disease of 1–5 years and no obvious complications, n = 56. The present study was approved by the Ethics Committee of The Affiliated Second Hospital of Chongqing Medical University (Chongqing, China), was conducted in accordance with the Declaration of Helsinki, and had the consent of all participants. T2DM was diagnosed according to the 1999 WHO diagnostic criteria. All of the participants enrolled were aged 20–60 years. The exclusion criteria for the study were as follows: 1) patients with types of diabetes other than T2DM, including type 1 diabetes, gestational diabetes or other specific types of diabetes, or who were taking multiple antidiabetic drugs, including insulin; 2) patients with liver and renal dysfunction, thyroid dysfunction, infectious diseases, severe cardiovascular vascular diseases, malignant tumors, or mental diseases. Subjects were further divided into subgroups according to sex. All peripheral blood samples were collected between 7 am and 9 am after 10–12 h of overnight fasting. Anthropometric parameters, such as height and weight, were measured according to standardized protocols. Systemic systolic blood pressure (SBP) and diastolic blood pressure (DBP)